Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
Expert Review of Hematology | February 10, 2026 | Volume: 19 | Issue: 5 | Pages: 539-546
10.1080/17474086.2026.2628534
| PMID 41666415